Intellectual property related to the Australian Life Sciences sector

Compiled by Stuart Roberts, Senior Analyst, stuart@ndfresearch.com, +61 447 247 909 (4 October 2017)

Here is a selection of recent PCT patent applications relevant to ASX-listed Life Sciences companies

Acrux (ASX; ACR)

WO/2016/015094, Topical composition, 4 February 2016

Admedus (ASX: AHX)

WO/2017/096432, Immunomodulating composition for treatment, 15 June 2017
WO/2016/049705, Therapeutic compositions and methods for inducing an immune response to Herpes Simplex Virus Type 2

AdAlta (ASX: 1AD)

WO/2016/109872, CXCR4 binding molecules, 14 July 2016

AFT Pharmaceuticals (ASX: AFT)

WO/2014/120021, A combination medicament comprising phenylephrine and paracetamol, 7 August 2014

Anatara Lifesciences (ASX: ANR)

WO/2017/031299, Enzymatic fractions with anti-inflammatory activity, 23 February 2017

Anteo Diagnostics (ASX: ADO)

WO/2017/083938, Method of controlled competitive exchange, 26 May 2017

Antisense Therapeutics (ASX: ANP)

WO/2014/197938, Combination therapy, 18 December 2014

Benitec (ASX: BLT)

WO/2017/177277, Reagents for treatment of Oculopharyngeal Muscular Dystrophy (OPMD) and use thereof, 19 October 2017
WO/2016/176745, Reagents for treatment of Hepatitis B Virus (HBV) infection and use thereof, 10 November 2016
WO/2014/107763, Age-Related Macular Degeneration treatment, 17 July 2014

Bionomics (ASX: BNO)

WO/2017/161414, Administration of an anti- LGR5 monoclonal antibody, 28 September 2017
WO/2016/197204, Pharmaceutical combination and uses thereof, 15 December 2016
WO/2016/138559, Combination treatment protocol, 9 September 2016
WO/2016/000012, Predicting response to cancer therapy, 7 January 2016
WO/2015/191799, Alpha-7 nicotinic acetylcholine receptor modulators and uses thereof, 17 December 2015
WO/2015/179893, A therapeutic protocol for treating ovarian cancer, 3 December 2015
WO/2015/123722, Inhibitors, 27 August 2015
WO/2014/138812, Salts, co-crystals, and polymorphs of an anxiolytic compound, 18 September 2014
WO/2014/138772, A crystalline form of an anxiolytic compound, 18 September 2014
WO/2014/036595, Compounds and methods for treating diseases or conditions associated with the central nervous system and/or neurite outgrowth, 13 March 2014

Cellmid (ASX: CDY)

WO/2017/147653, Methods of treating bone diseases, disorders and/or injuries and reagents therefor, 8 September 2017
WO/2016/058047, Improved midkine antibody, 21 April 2016
WO/2015/085373, Method of treatment of alopecia with monoterpenoids, 18 June 2015

Clover Corporation (ASX: CLV)

WO/2017/177283, Methods of manufacturing nutritional formulations, 19 October 2017

CSL Ltd (CSL)

WO/2017/181243, Method of treating or preventing liver conditions, 26 October 2017
WO/2017/173494, Method of treating atherosclerosis, 12 October 2017
WO/2017/117631, Mutated truncated von Willebrand factor, 13 July 2017
WO/2017/117630, Mutated von Willebrand factor, 13 July 2017
WO/2017/088028, CD131 binding proteins and uses thereof, 1 June 2017
WO/2016/077878, Method of treating or preventing stroke, 26 May 2016
WO/2016/020210, Factor VIII formulation, 11 February 2016
WO/2016/000039, Modified Von Willebrand Factor, 7 January 2016
WO/2015/154139, Half-life extended Factor FVIIIa protein for prevention and treatment of bleeding and dosing regimens therefor, 15 October 2015
WO/2015/095925, Fusion proteins comprising Factor IX for prophylactic treatment of hemophilia and methods thereof, 2 July 2015
WO/2015/089585, Method of treating wounds, 25 June 2015
WO/2015/077845, Method of treating nephropathy, 4 June 2015
WO/2015/077844, Method of treating cancer, 4 June 2015
WO/2015/017888, Contaminant removal method, 12 February 2015
WO/2014/194362, Process for preparing Apolipoprotein A-I (APO A-I), 11 December 2014
WO/2014/173873, Complex, 30 October 2014
WO/2014/138819, Agents that neutralize Il-3 signaling and uses thereof, 18 September 2014
WO/2014/138805, Anti Il-3r alpha agents and uses thereof, 18 September 2014
WO/2014/121325, Il-11r binding proteins and uses thereof, 14 August 2014
WO/2014/066943, Reconstituted HDL formulation, 8 May 2014
WO/2014/015388, A method for polishing albumin, 30 January 2014

Cyclopharm (ASX: CYC)

WO/2014/063198, A radioisotope concentrator, 1 May 2014

Cynata Therapeutics (ASX: CYP)

WO/2017/156580, Colony forming medium and use thereof, 21 September 2017

EVE Investments (ASX: EVE)

WO/2016/168897, Pharmaceutical powder composition and its use in the control of post-prandial glycaemic profile, Omniblend Innovation, 27 October 2016
WO/2015/074103, Regimen and method for treatment of Type 2 Diabetes, Omniblend Innovation, 28 May 2015
WO/2015/074102, Composition and method for control of post-prandial glucose, Omniblend Innovation, 28 May 2015

Immuron (ASX: IMC)

WO/2014/169344, Methods and compositions for the treatment and/or prophylaxis of Clostridium Difficile associated disease, 23 October 2014

Imugene (ASX: IMU)

WO/2016/164980, A vaccine composition and uses thereof, 20 October 2016

Innate Immunotherapeutics (ASX: IIL)

WO/2017/070731, Compositions and methods for the treatment of Alzheimer's disease, 4 May 2017
WO/2017/059486, Compositions and methods for the treatment of epilepsy, 13 April 2017
WO/2017/059485, Compositions and methods for protection and/or repair of the nervous system, 13 April 2017

Living Cell Technologies (ASX: LCT)

WO/2016/187067, Treatment of CNS disease with encapsulated inducible choroid plexus cells, 24 November 2016
WO/2014/171842, Biocompatible encapsulation system, 23 October 2014

Mayne Pharma (ASX: MYC)

WO/2014/172456, Treatment and prognostic monitoring of proliferation disorders using hedgehog pathway inhibitors, 23 October 2014 (with Hedgepath Pharmaceuticals)

Medlab Clinical (ASX: MDC)

WO/2016/065419, Treatment for depression and depressive disorders, 6 May 2016
WO/2015/172191, Probiotic compositions and uses thereof for treatment of obesity-related disorders, 19 November 2015

Neuren Pharmaceuticals (ASX: NEU)

WO/2015/013397, Neuroprotective bicyclic compounds and methods for their use in treating autism spectrum disorders and neurodevelopmental disorders, 29 January 2015
WO/2014/085480, Treatment of Autism Spectrum Disorders using Glycyl-L-2-Methylprolyl-L-Glutamic Acid, 5 June 2014

Novogen (ASX: NRT)

WO/2016/187667, Functionalised and substituted indoles as anti-cancer agents, 1 December 2016
WO/2016/008011, Functionalised and substituted indoles as anti-cancer agents, 21 January 2016
WO/2016/008010, Functionalised and substituted carbazoles as anti-cancer agents, 21 January 2016
WO/2015/117202, Functionalised benzopyran compounds and use thereof, 13 August 2015
WO/2015/074124, Functionalised and substituted indoles as anti-cancer agents, 28 May 2015
WO/2015/074123, Functionalised and substituted indoles as anti-cancer agents, 28 May 2015

Noxopharm (ASX: NOX)

WO/2017/181242, Chemotherapy improvements, 26 October 2017
WO/2017/173498, Isoflavonoid composition with improved pharmacokinetics, 12 October 2017
WO/2017/173497, Targeted drug delivery, 12 October 2017
WO/2017/173496, Radiotherapy improvements, 12 October 2017
WO/2017/173474, Improvements in cancer treatment, 12 October 2017

Opthea (ASX: OPT)

WO/2015/123715, Ligand binding molecules and uses thereof, 27 August 2015
WO/2014/124487, Ligand binding molecules and uses thereof, 21 August 2014

PharmAust (ASX: PAA)

WO/2016/137010, Anti cancer agent comprising aminoacetonitrile compound as active ingredient, 1 September 2016 (with Nihon Nohyaku Co.)
WO/2015/061832, Pharmaceutical combinations for the treatment of cancer, 7 May 2015
WO/2015/037747, Anticancer agent comprising aminoacetonitrile compound as active ingredient, 19 March 2015 (with Nihon Nohyaku Co.)
WO/2014/094041, Treatment of diseases involving mucin, 26 June 2014
WO/2014/022879, Compounds for the treatment of mTOR pathway related diseases, 13 February 2014

Pharmaxis (ASX: PXS)

WO/2017/136871, Indole and azaindole haloallylamine derivative inhibitors of lysyl oxidases and uses thereof, 17 August 2017
WO/2017/136870, Haloallylamine indole and azaindole derivative inhibitors of lysyl oxidases and uses thereof, 17 August 2017

Phosphagenics (ASX: POH)

WO/2017/096427, Pharmaceutical formulation, Phosphagenics Ltd, 15 June 2017

Prana Biotechnology (ASX: PBT)

WO/2016/086261, 4H-Pyrido[1,2-A]Pyrimidin-4-one compounds, 9 June 2016

Recce (ASX: RCE)

WO/2017/139849, Anti-virus agent and method for treatment of viral infection, 24 August 2017
WO/2016/077879, Copolymer and method for treatment of bacterial infection, 26 May 2016

Regeneus (ASX: RGS)

WO/2017/041133, Cell expansion methods and therapeutic compositions, 16 March 2017
WO/2015/048842, Biomarkers for cell therapy, 9 April 2015
WO/2014/100857, Vaccines for the treatment of cancer and compositions for enhancing vaccine efficacy, 3 July 2014

Sirtex Medical (ASX: SRX)

WO/2015/168726, Method for treating renal cell carcinoma, 12 November 2015
WO/2015/109367, Treatment of neoplasia, 30 July 2015

Starpharma (ASX: SPL)

WO/2015/184510, Dendrimer-drug conjugates, 10 December 2015
WO/2015/035446, Macromolecules of dendrimer-platinum conjugates, 19 March 2015
WO/2014/043576, Method of treatment or prophylaxis of infections of the eye, 20 March 2014

Vectus Biosystems (ASX: VBS)

WO/2016/145479, Compositions for the treatment of fibrosis and fibrosis-related conditions, 22 September 2016
WO/2016/145478, Compositions for the treatment of kidney and/or liver disease, 22 September 2016
WO/2015/039173, Compositions for the treatment of hypertension and/or fibrosis, 26 March 2015
WO/2015/039172, Compositions for the treatment of hypertension and/or fibrosis, 26 March 2015

Viralytics (ASX: VLA)

WO/2015/127501, Combination method for treatment of cancer, 3 September 2015
WO/2014/201492, Methods for the treatment of bladder cancer, 24 December 2014